Lonza and Integral Molecular partner on biotherapeutics
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Subscribe To Our Newsletter & Stay Updated